EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Dexamethasone is non-inferior to antihistamine plus dexamethasone premedication in preventing ramucirumab plus nab-paclitaxel infusion-related reactions in gastric cancer: a multicenter retrospective study

Yutaka Negoro, Taichi Maeda, Hiroyuki Igarashi, Mina Shigemori, Toshihiro Tanaka, Yukio Ito, Norihiko Tanizawa, Shota Nishikawa, Jyunya Ogawa, Yukio Kamitani, Kyohei Watanabe, Hitoshi Tsukamoto und 1 weitere

Supportive Care in Cancer · 2024

DOI: 10.1007/s00520-024-08910-8 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Supportive Care in Cancer, 2024. Verfasst von Yutaka Negoro und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Fukui Hospital, Yoshida-Gun, 23-3 Matsuoka-Shimoaizuki, Eiheiji-Cho, Fukui, Japan. ynegoro@u-fukui.ac.jp. Hauptthemen laut MEDLINE: Stomach Neoplasms, Antibodies, Monoclonal, Humanized, Dexamethasone, Ramucirumab. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Fukui.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Ramucirumab (RAM) is recommended as premedication with H 1 -receptor antagonists (H 1 RA) to prevent infusion-related reactions (IRRs). However, RAM is a human antibody with a low incidence of IRRs. We evaluated the noninferiority of non-H 1 RA (dexamethasone [DEX] alone) premedication to H 1 RA (plus DEX) premedication in terms of IRRs in patients with gastric cancer receiving RAM plus nanoparticle albumin-bound paclitaxel (nab-PTX).

Methods

This was a noninferiority, multicenter, retrospective trial conducted in three Japanese centers to assess the incidence of IRRs in patients receiving RAM plus nab-PTX for gastric cancer between 2018 and 2023. Patients with gastric cancer receiving RAM plus nab-PTX were divided into groups with and without H 1 RA premedication. The incidence of IRRs was compared between the two groups.

Results

Ninety patients were evaluated, with non-H 1 RA and H 1 RA premedications in 43 and 47 cases, respectively. After the first dose of RAM, IRRs were not observed in either group. IRRs during the overall doses were 0% for non-H 1 RA premedication and 2.1% for H 1 RA premedication (90% confidence interval (CI): –5.6%–1.3% for each comparison). The upper limit of the 90% CI (1.3%) did not exceed the noninferiority margin (Δ) of + 10% and therefore met the noninferiority criteria.

Conclusion

RAM plus nab-PTX for gastric cancer with DEX premedication may be possible without H 1 RA premedication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsAntibodies, Monoclonal, HumanizedDexamethasoneRamucirumabPremedicationPaclitaxelAntineoplastic Combined Chemotherapy ProtocolsAlbuminsHumansRetrospective StudiesFemaleMaleAgedMiddle AgedJapanAdultAged, 80 and over

Stichwörter der Autor:innen

Antihistamines premedicationGastric cancerInfusion-related reactionsNab-PaclitaxelRamucirumab

Substanzen

Antibodies, Monoclonal, HumanizedDexamethasoneRamucirumabPaclitaxel130-nm albumin-bound paclitaxelAlbumins

Autor:innen und Institutionen

  • Department of Pharmacy, University of Fukui Hospital, Yoshida-Gun, 23-3 Matsuoka-Shimoaizuki, Eiheiji-Cho, Fukui, Japan. ynegoro@u-fukui.ac.jp.
  • Department of Pharmacy, Japanese Red Cross Fukui Hospital, Fukui, Japan.
  • Department of Pharmacy, Fukui-Ken Saiseikai Hospital, Fukui, Japan.
  • Department of Pharmacy, University of Fukui Hospital, Yoshida-Gun, 23-3 Matsuoka-Shimoaizuki, Eiheiji-Cho, Fukui, Japan.
  • Medical Research Support Center, University of Fukui Hospital, Yoshida-Gun, Fukui, Japan.

Förderung

  • University of Fukui

Zitieren

APA

Negoro, Y., Maeda, T., Igarashi, H., Shigemori, M., Tanaka, T., Ito, Y., Tanizawa, N., Nishikawa, S., Ogawa, J., Kamitani, Y., Watanabe, K., Tsukamoto, H., & Goto, N. (2024). Dexamethasone is non-inferior to antihistamine plus dexamethasone premedication in preventing ramucirumab plus nab-paclitaxel infusion-related reactions in gastric cancer: a multicenter retrospective study. Supportive Care in Cancer. https://doi.org/10.1007/s00520-024-08910-8

Vancouver

Negoro Y, Maeda T, Igarashi H, Shigemori M, Tanaka T, Ito Y, et al. Dexamethasone is non-inferior to antihistamine plus dexamethasone premedication in preventing ramucirumab plus nab-paclitaxel infusion-related reactions in gastric cancer: a multicenter retrospective study. Supportive Care in Cancer. 2024. doi:10.1007/s00520-024-08910-8

BibTeX
@article{Negoro2024,
  author = {Negoro, Yutaka and Maeda, Taichi and Igarashi, Hiroyuki and Shigemori, Mina and Tanaka, Toshihiro and Ito, Yukio and Tanizawa, Norihiko and Nishikawa, Shota and Ogawa, Jyunya and Kamitani, Yukio and Watanabe, Kyohei and Tsukamoto, Hitoshi and Goto, Nobuyuki},
  title = {Dexamethasone is non-inferior to antihistamine plus dexamethasone premedication in preventing ramucirumab plus nab-paclitaxel infusion-related reactions in gastric cancer: a multicenter retrospective study},
  journal = {Supportive Care in Cancer},
  year = {2024},
  doi = {10.1007/s00520-024-08910-8}
}
Kostenlos starten →